The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With U-500 Insulin

Summary

The aim of this study is to evaluate the effect of adding a SGLT-2 inhibitor (namely Canagliflozin) on the dose of U-500 insulin required to achieve glycemic control in patients with type 2 diabetes. We hypothesize that adding Canagliflozin to patients treated with U-500 insulin may result in significant reduction in insulin dose due to improved insulin sensitivity and weight loss.

Timeline

Start

2015-11

Primary completion

2017-07

Completion

2017-07

Drugs

Indications